A Sample Collection Study to Validate the Astute Medical NephroCheck Test in Critically Ill Subjects at Risk for Acute Kidney Injury

Acute Kidney Injury Clinical Trial

Official title:

A Sample Collection Study to Validate the Astute Medical NephroCheck Test in Critically Ill Subjects at Risk for Acute Kidney Injury

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01573962
• Other study ID #: Topaz
• Status: Completed
• Phase: N/A
• First received: April 6, 2012
• Last updated: October 13, 2014
• Start date: April 2012
• Est. completion date: December 2012

Study information

• Verified date: September 2013
• Source: Astute Medical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The objective of this sample collection study is to collect blood and urine samples. This study is observational and will have no impact on the medical management of the subject.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 420
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Males and females 21 years of age or older

• Subjects must be enrolled (first study-specific sample collection) within 24 hours of ICU admission

• Subjects enrolled from ED or Floor must be admitted to the ICU within 24 hours of enrollment

• Subjects enrolled in the ICU must have been admitted to the ICU or transferred into the study ICU from another ICU no more than 24 hours prior to enrollment

• Expected to remain in the ICU for at least 48 hours after enrollment

• Use of indwelling urinary catheter as standard care expected for at least 48 hours after enrollment

• At least one of the following acute conditions documented within 24 hours prior to enrollment

• Respiratory SOFA score of = 2 (PaO2/FiO2 <300)

• Cardiovascular SOFA score of = 1 (MAP < 70 mm Hg and/or any vasopressor required

• Subject (or authorized representative) able and willing to provide written informed consent for study participation.

Exclusion Criteria:

• Special populations including women with known pregnancy, prisoners or institutionalized individuals

• Previous renal transplantation

• Known moderate to severe AKI prior to enrollment (e.g., RIFLE-I or RIFLE-F/ AKIN 2 or AKIN 3

• Already receiving dialysis (either acute or chronic) or in imminent need of dialysis at the time of enrollment

• Known infection with human immunodeficiency virus (HIV) or active hepatitis (acute or chronic)

• Subjects with a history of Chronic Kidney Disease (CKD) without a baseline serum creatinine value (baseline within 6 months of enrollment)

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acute Kidney Injury
• Critical Illness

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Astute Medical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	A Sample Collection Study to Validate the Astute Medical NephroCheck Test in Critically Ill Subjects at Risk for Acute Kidney Injury		04/1/2012 to 3/29/13	No